SCM
CBAY

Stonepine Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Stonepine Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-300,000
Closed -$1.01M – 31
2021
Q4 		$1.01M Buy
+300,000
New +$1.14M 0.47% 20

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Stonepine Capital Management's CBAY Position: Q1 2022 in Review

Stonepine Capital Management sold out of Cymabay Therapeutics (CBAY) in Q1 2022, closing a stake of 300,000 shares — an estimated $1.01M sold.

Stonepine Capital Management first reported a position in CBAY in Q4 2021 and held it in 1 quarter. The position peaked at $1.01M in Q4 2021. 118 funds tracked by Wall St. Rank hold CBAY as of Q1 2022.

  • Stonepine Capital Management reported no remaining Cymabay Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Stonepine Capital Management sold 300,000 Cymabay Therapeutics shares in Q1 2022, an estimated $1.01M.
  • Stonepine Capital Management first reported a position in Cymabay Therapeutics in Q4 2021 and held it in 1 quarter.
  • Stonepine Capital Management's Cymabay Therapeutics position peaked at $1.01M in Q4 2021.
  • 118 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2022.

Based on Stonepine Capital Management's 13F filing for Q1 2022, filed 16 May 2022.